BIIB 10-K Analysis: The $957M Earnings Gap Between Two Biogen Valuations
Biogen reported GAAP EPS of $8.79 — a 21% decline — while simultaneously beating Non-GAAP guidance at $15.28 per share. The $957 million gap between these two numbers is the widest percentage divergence among large-cap biotechs. The 10-K reveals that 'core' operating income actually improved 1%, that the U.S. franchise grew 12.9% while Biogen physically retreated from European markets, and that anti-CD20 royalty margins at 56% are structurally compressing profitability even as headline revenue stabilizes. At 14.1x adjusted operating earnings with zero shareholder returns, the stock is a bet on whether $5.3 billion in pipeline commitments can replace what the MS franchise is losing.